Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Cassava Sciences, Inc. - Common Stock (NQ:SAVA)

2.030 +0.140 (+7.41%)
Streaming Delayed Price Updated: 4:00 PM EST, Feb 6, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Cassava Sciences, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
21 22 Next >
News headline image
This Goldman Sachs Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday ↗
 
Via Benzinga
News headline image
Cassava Sciences, Zoom, Kohl's, Rivian, Tesla: Why These 5 Stocks Are On Investors' Radars Today ↗
SAVA, ZM, KSS, RIVN, TSLA were among the trending stocks among investors on Monday Nov. 25, 2024. 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Monday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Gold Down Over 3%; Rigetti Computing Shares Spike Higher ↗
 
Via Benzinga
News headline image
Crude Oil Down 3%; Chicago Fed National Activity Index Falls In October ↗
 
Via Benzinga
Topics Economy
News headline image
Unpacking the Latest Options Trading Trends in Cassava Sciences ↗
 
Via Benzinga
News headline image
How Is The Market Feeling About Cassava Sciences? ↗
 
Via Benzinga
News headline image
$1000 Invested In This Stock 5 Years Ago Would Be Worth $20,000 Today ↗
 
Via Benzinga
News headline image
'Pharma Bro' Martin Shkreli Tells Investors To 'Short SAVA,' Stock Falls Over 80% After Phase 3 Update ↗
Pharma bro Martin Shkreli predicted Cassava Sciences stock would fall and the company would miss primary endpoints for its Phase 3 trial. 
Via Benzinga
News headline image
Dow Surges Over 300 Points; Bath & Body Works Posts Upbeat Earnings ↗
 
Via Benzinga
Topics Stocks
News headline image
Cassava Sciences Alzheimer's Drug Fails To Hit Primary Goal In Pivotal Study, Pharma Halts Late-Stage Studies ↗
Cassava Sciences' stock fell after Phase 3 simufilam trial failed to meet key endpoints, prompting the discontinuation of its Alzheimer's studies. 
Via Benzinga
News headline image
Cassava Sciences Plummets 85% After Embattled Alzheimer's Drug Flops ↗
The company tested simufilam in patients with mild-to-moderate Alzheimer's disease. 
Via Investor's Business Daily
News headline image
Cassava Sciences, Biohaven And Other Big Stocks Moving Lower In Monday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Cassava Sciences Unusual Options Activity ↗
 
Via Benzinga
News headline image
Friday's Top 5 Trending Stocks: What's The Scoop On GameStop, SoFi, Tesla? ↗
GameStop, SoFi, Tesla, Cassava Sciences and Anavex Life Sciences are the top five trending stocks on Stocktwits Friday. Here's a look at what's going on: 
Via Benzinga
News headline image
Analysts Believe Cassava Sciences Now Has 300% Upside From Here
Cassava Sciences faces controversy over its Alzheimer's drug, simufilam, amid fraud allegations, yet analysts maintain a Buy rating with high upside potential. 
Via MarketBeat
Topics Fraud Lawsuit
News headline image
10 Health Care Stocks With Whale Alerts In Today's Session ↗
 
Via Benzinga
News headline image
Crude Oil Falls Over 4%; US Trade Deficit Narrows In August ↗
 
Via Benzinga
News headline image
What's Going On With Alzheimer's-Focused Cassava Sciences On Tuesday? ↗
Cassava Sciences Inc. has agreed to a $40 million settlement over SEC charges related to misleading data for simufilam. The firm anticipates top-line results from the ReTHINK Phase 3 trial before... 
Via Benzinga
Topics Regulatory Compliance
News headline image
PepsiCo, DocuSign, Robinhood And Other Big Stocks Moving Higher On Tuesday ↗
 
Via Benzinga
News headline image
This Wells Fargo Analyst Turns Bullish; Here Are Top 5 Upgrades For Tuesday ↗
 
Via Benzinga
News headline image
Nano-Cap Bio-Path Takes Plunge In Weight Loss Race, Initiates Obesity Program With Drug Candidate Under Development For Blood Cancer ↗
Bio-Path is advancing its obesity treatment BP1001-A and completing trials for BP1002 in acute myeloid leukemia, targeting resistance mechanisms in treatment. Preclinical studies for obesity are set... 
Via Benzinga
News headline image
10 Health Care Stocks Whale Activity In Today's Session ↗
 
Via Benzinga
News headline image
Why Cassava Sciences Stock Dived by Almost 11% Today ↗
Without admitting wrongdoing, the company put a regulatory controversy to rest, but this was expensive. 
Via The Motley Fool
News headline image
Cassava Sciences, enVVeno Medical And Other Big Stocks Moving Lower In Friday's Pre-Market Session ↗
 
Via Benzinga
News headline image
SEC Charges Cassava Sciences Over Manipulated Alzheimer's Trial Data, Company And Former Execs Agree To Pay Penalty ↗
Cassava Sciences and its executives face a $40 million SEC settlement over manipulated data in an Alzheimer's drug trial, misleading investors with false claims of cognitive improvement and selective... 
Via Benzinga
Topics Regulatory Compliance
News headline image
12 Health Care Stocks Moving In Friday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Why Establishment Labs Shares Are Trading Higher By Around 28%; Here Are 20 Stocks Moving Premarket ↗
 
Via Benzinga
News headline image
Cassava Sciences Stock Rises On Interim Safety Review Of Simufilam Phase 3 Trials ↗
Cassava Sciences, Inc. (NASDAQ: SAVA) shares trading higher following the announcement of a positive interim safety review of its Alzheimer's drug candidate, simufilam. Here's what you need to know. 
Via Benzinga
News headline image
9 Health Care Stocks Whale Activity In Today's Session ↗
 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
21 22 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.